{"filing":{"accession_number":"0001140361-26-040186","cik":"0002017526","ticker":"PCSC","company_name":"Freenome, Inc.","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"ef20084075_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2017526/000114036126040186/ef20084075_8k.htm"},"events":[{"id":36307,"run_id":33474,"accession_number":"0001140361-26-040186","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Freenome announced the launch of SimpleScreen™ Lung, a laboratory-developed blood-based test for lung cancer screening, and introduced a 'Personalized Cancer Detection' portfolio approach enabling dual screening for lung and colorectal cancer through a single blood draw. The lung cancer test demonstrated 85% sensitivity and 99.8% negative predictive value, representing a material product launch and portfolio expansion for the early-stage cancer detection company.","company_name":"Freenome, Inc.","ticker":"PCSC","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40677,"accession_number":"0001140361-26-040186","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Freenome announced the launch of SimpleScreen™ Lung, a laboratory-developed test for lung cancer screening, and introduced a \"Personalized Cancer Detection\" portfolio approach enabling dual screening for lung and colorectal cancer through a single blood draw. This is a material product launch and portfolio expansion for an early-stage cancer detection company, but does not fit neatly into earnings, M\u0026A, governance, or financial categories—it is a strategic operational and commercial milestone involving a new clinical offering and market expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:53:41.140428+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40678,"accession_number":"0001140361-26-040186","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Freenome announced the launch of SimpleScreen™ Lung, a new blood-based cancer screening test, and a first-of-its-kind dual-cancer screening offering combining lung and colorectal cancer detection through a single blood draw. This represents a material product launch and portfolio expansion for an early-stage diagnostics company, with clinical validation data (85% sensitivity, 99.8% NPV for lung cancer) disclosed. While not fitting the specific operational categories (no M\u0026A, workforce reduction, or major contract), this is clearly a material operational/strategic milestone—the launch of a new validated diagnostic product—that would affect investor assessment of the company's commercial prospects and pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:53:41.140428+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40677,"accession_number":"0001140361-26-040186","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Freenome announced the launch of SimpleScreen™ Lung, a laboratory-developed test for lung cancer screening, and introduced a \"Personalized Cancer Detection\" portfolio approach enabling dual screening for lung and colorectal cancer through a single blood draw. This is a material product launch and portfolio expansion for an early-stage cancer detection company, but does not fit neatly into earnings, M\u0026A, governance, or financial categories—it is a strategic operational and commercial milestone involving a new clinical offering and market expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:53:41.140428+00:00","company_name":"Freenome, Inc.","ticker":"PCSC","filing_date":"2026-10-20"},{"id":40678,"accession_number":"0001140361-26-040186","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Freenome announced the launch of SimpleScreen™ Lung, a new blood-based cancer screening test, and a first-of-its-kind dual-cancer screening offering combining lung and colorectal cancer detection through a single blood draw. This represents a material product launch and portfolio expansion for an early-stage diagnostics company, with clinical validation data (85% sensitivity, 99.8% NPV for lung cancer) disclosed. While not fitting the specific operational categories (no M\u0026A, workforce reduction, or major contract), this is clearly a material operational/strategic milestone—the launch of a new validated diagnostic product—that would affect investor assessment of the company's commercial prospects and pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:53:41.140428+00:00","company_name":"Freenome, Inc.","ticker":"PCSC","filing_date":"2026-10-20"}]}